AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure
As FDA Adds Major Approval To Diabetes Drug's Label
AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.
You may also be interested in...
Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
Jardiance and Ofev are growing strongly but the German drugmaker is also confident its pipeline will bear fruit, boosted by a rising research budget that represents almost 23% of sales.